In the near future, the FDA has no plans to regulate the legality of sales of CBD products in the United States.

The Authority cannot accept any market practice without additional data on the safety of CBD products. Companies that sell products containing cannabidiol in their formulation in the form of food or dietary supplements violate the Law on Food, Drugs and Cosmetics.

Despite pressure from various types of structures intending to regulate the use of a significant number of products that contain cannabinoids, the Food and Drug Administration (FDA) has not yet created or plans in the near future to approve a regulatory framework governing the legality of the marketing and sale of commercial products containing plant-based cannabidiol.

In particular, speaking at the November 2021 National Technical Hemp Business Summit in Washington, FDA spokeswoman Gail Sipes said that this government agency cannot adopt any rules for working in the market without additional data on the safety of CBD products. She reiterated the FDA's position that companies that sell products containing cannabidiol in their formulations in the form of food or dietary supplements are in violation of the Food, Drug and Cosmetic Act.

Commentary of the specialists of the Association "Ukrainian technical hemp"

Analyzes and tests, regularly conducted by the FDA and other organizations, invariably report that many CBD products are of varying quality, and the effectiveness of therapeutic properties in most of them is extremely questionable. In addition, some CBD food products, various additives, cosmetics or pharmaceuticals contain various types of heavy metals or other substances that threaten the safety of consumers / patients. In addition, data from a poll conducted last year by the National League of Consumers show that more than eight in ten US voters want increased federal regulatory oversight of the labeling and marketing of commercially available cannabidiol-containing products.